Please assess the completion status of the following clinical trial:

Trial Title: Arresting Vertical Transmission of Hepatitis B Virus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Pregnant women receiving care at Binza and Kingasani maternity centers presenting prior to 24 weeks gestation~* Infants born to HBV-positive women~Exclusion criteria:~* Participants who are severely sick and who require prolonged hospitalization.~* Any women who do not intend to stay in Kinshasa for prenatal care through delivery

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk HBV dyads (Type: EXPERIMENTAL): Mothers with high-risk HBV (defined as viral load \>10\^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
- Low-risk HBV dyads (Type: EXPERIMENTAL): Mothers with low risk HBV (defined as a viral load \<10\^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).